Search

Your search keyword '"Maimone, Santo"' showing total 154 results
Start Over Author "Maimone, Santo"
154 results on '"Maimone, Santo"'

18. Abstract P3-05-25: Clinical Factors associated with Survival Outcomes in Patients with Metaplastic Breast Cancer

Author

Chinniah, Siven, primary, Zarrar, Raza, additional, Li, Zhuo, additional, Sideras, Kostandinos, additional, Moreno-Aspitia, Alvaro, additional, Chumsri, Saranya, additional, Rao, Rohit, additional, McLaughlin, Sarah, additional, Jakub, James, additional, Gabriel, Emmanuel, additional, Bagaria, Sanjay, additional, Vallow, Laura, additional, Maimone, Santo, additional, and Advani, Pooja, additional

Published
2023
Full Text
View/download PDF

26. Patient uptake of updated genetic testing following uninformative BRCA1 and BRCA2 results.

Author

Macklin‐Mantia, Sarah K., Clift, Kristin E., Maimone, Santo, Hodge, David O., Riegert‐Johnson, Douglas, and Hines, Stephanie L.

Abstract

Advances have dated the genetic testing initially offered to evaluate for hereditary breast and ovarian cancer risks. Previous research has demonstrated that many patients have not updated testing. This study reviewed the incidence of additional analysis after an uninformative BRCA1/2 result and offered updated testing with limited barriers to those who had not completed. After viewing an educational video and providing informed consent, eligible patients were mailed a saliva collection kit to complete an 84‐gene hereditary cancer panel at no personal cost. A total of 704 patients had completed BRCA1/2 only testing between 2001 and 2020. Fifteen percent (N = 102) of the 671 patients with an uninformative BRCA1/2 result had already completed expanded testing. Most, 74 of 102 (73%), had been rereferred to medical genetics during a clinical visit related to cancer care. Those who had already completed additional testing were more likely to have a personal history of cancer (92% vs. 79%, p = 0.002) and live locally (p = 0.032). Invitation to complete updated testing through this study was sent to 372 people, and 116 (31%) consented to participate. For 142 of the 256 who did not proceed with testing through the study, proof of receipt of research information was available. In total, 22 pathogenic variants were reported in 21 of the 226 patients with updated testing from before and including our study: ATM (4), CHEK2 (4), LZTR1 (1), MUTYH (3), NBN (1), NF1 (1), NTHL1 (1), PALB2 (4), PMS2 (1), RAD50 (1), and SPINK1 (1). Many potential barriers of retesting were eliminated by removing personal costs or travel requirements. Still, only about 30% of patients agreed to participate, and a significant portion elected not to proceed. Future research could focus on the discovery of other factors that dissuade patients and what measures may better inform them on potential benefits. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

30. Use of Artificial Intelligence for Digital Breast Tomosynthesis Screening: A Preliminary Realworld Experience.

Author

Letter, Haley, Peratikos, Meridith, Toledano, Alicia, Hoffmeister, Jeffrey, Nishikawa, Robert, Conant, Emily, Shisler, Julie, Maimone, Santo, and de Villegas, Hector Diaz

Subjects
BREAST tumor diagnosis, AUDITING, BIOPSY, CONFIDENCE intervals, ARTIFICIAL intelligence, EARLY detection of cancer, MAMMOGRAMS, RETROSPECTIVE studies, DESCRIPTIVE statistics, DATA analysis software, ODDS ratio
Abstract

Objective: The purpose of this study is to assess the "real-world" impact of an artificial intelligence (AI) tool designed to detect breast cancer in digital breast tomosynthesis (DBT) screening exams following 12 months of utilization in a subspecialized academic breast center. Methods: Following IRB approval, mammography audit reports, as specified in the BI-RADS atlas, were retrospectively generated for five radiologists reading at three locations during a 12-month time frame. One location had the AI tool (iCAD ProFound AI v2.0), and the other two locations did not. The co-primary endpoints were cancer detection rate (CDR) and abnormal interpretation rate (AIR). Secondary endpoints included positive predictive values (PPVs) for cancer among screenings with abnormal interpretations (PPV1) and for biopsies performed (PPV3). Odds ratios (OR) with two-sided 95% confidence intervals (CIs) summarized the impact of AI across radiologists using generalized estimating equations. Results: Nonsignificant differences were observed in CDR, AIR, and PPVs. The CDR was 7.3 with AI and 5.9 without AI (OR 1.3, 95% CI: 0.9--1.7). The AIR was 11.7% with AI and 11.8% without AI (OR 1.0, 95% CI: 0.8--1.3). The PPV1 was 6.2% with AI and 5.0% without AI (OR 1.3, 95% CI: 0.97--1.7). The PPV3 was 33.3% with AI and 32.0% without AI (OR 1.1, 95% CI: 0.8--1.5). Conclusion: Although we are unable to show statistically significant changes in CDR and AIR outcomes in the two groups, the results are consistent with prior reader studies. There is a nonsignificant trend toward improvement in CDR with AI, without significant increases in AIR. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

32. Abstract P3-03-19: Incidence and time to resolution of axillary adenopathy on mammography after COVID-19 vaccination

Author

Robinson, Kristin, primary, Maimone, Santo, additional, Advani, Pooja P, additional, Li, Zhuo, additional, Gococo-Benore, Denise, additional, Qosja, Neda, additional, Mummareddy, Ashita, additional, Ashai, Ahmed M, additional, Wilhelm, Annamaria, additional, Maxwell, Robert, additional, Wasserman, Martha, additional, Patel, Neema, additional, Morozov, Andrey, additional, and Chumsri, Saranya, additional

Published
2022
Full Text
View/download PDF

39. A Validated Nomogram to Predict Upstaging of Ductal Carcinoma in Situ to Invasive Disease

Author

Jakub, James W., primary, Murphy, Brittany L., additional, Gonzalez, Alexandra B., additional, Conners, Amy L., additional, Henrichsen, Tara L., additional, Maimone, Santo, additional, Keeney, Michael G., additional, McLaughlin, Sarah A., additional, Pockaj, Barbara A., additional, Chen, Beiyun, additional, Musonza, Tashinga, additional, Harmsen, William S., additional, Boughey, Judy C., additional, Hieken, Tina J., additional, Habermann, Elizabeth B., additional, Shah, Harsh N., additional, and Degnim, Amy C., additional

Published
2017
Full Text
View/download PDF

42. Value of Axillary Ultrasound after Negative Axillary MRI for Evaluating Nodal Status in High-Risk Breast Cancer

Author

Almerey, Tariq, Villacreses, Diego, Li, Zhuo, Patel, Bhavika, McDonough, Mary Ann, Gibson, Tammeza, Maimone, Santo, Gray, Richard, and McLaughlin, Sarah A.

Abstract

It is assumed axillary ultrasound (AxUS) is the best method for axillary nodal evaluation in newly diagnosed breast cancer patients. However, few have evaluated the efficacy of preoperative axillary MRI. Herein, we compare the statistical accuracy of AxUS and MRI in detecting nodal metastases among breast cancer patients who were selected for neoadjuvant chemotherapy.

Published
2024
Full Text
View/download PDF

47. Breast Findings at Chest CT

Author

Stowell, Justin T., Grage, Rolf A., Cortopassi, Isabel O., Little, Brent P., and Maimone, Santo

Abstract

Chest CT images include breast tissue, and although CT is not the preferred modality for optimal breast evaluation, familiarity with expected and unexpected imaging findings facilitates appropriate management of abnormal breast findings.

Published
2023
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results